STOCK TITAN

Reshape Lifesciences Inc. - RSLS STOCK NEWS

Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.

Reshape Lifesciences, Inc. is a medical device company focused on the development of non-surgical weight loss devices for obese or overweight patients. The company offers a range of innovative products, including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation. Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the growing demand for safe and effective options in the market.

Rhea-AI Summary

ReShape Lifesciences (NASDAQ: RSLS) has launched a comprehensive advertising campaign to promote its Next-Generation Lap-Band Program, aiming to increase patient demand. This multi-platform initiative includes national television ads on popular channels and print advertisements in major consumer publications. The campaign responds to the significant rise in obesity, projected to affect nearly half the adult population by 2030. ReShape's goal is to build brand awareness and drive procedural volumes, leveraging data from historical marketing efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
-
Rhea-AI Summary

ReShape Lifesciences (NASDAQ:RSLS) was featured in BioTuesdays, highlighting its role in addressing obesity-related health issues. CEO Bart Bandy emphasized the company's comprehensive approach to weight loss solutions, differentiating from competitors focused on single therapies. Their lead product, Lap-Band®, has over 1 million placements globally, offering a minimally invasive option for obesity treatment. ReShape aims to support patients through various products, including the investigational ReShape Vest™ and the virtual reshape™ program, targeting the growing health crisis of obesity and metabolic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary

ReShape Lifesciences (NASDAQ:RSLS) will exhibit at the 17th Annual Bariatric Summit in Washington, D.C., on September 18-19, 2021. Heather Mackie, Director of reshapecare™, will present during key patient care sessions. The summit aims to foster discussions among healthcare professionals on obesity-related conditions and integrated weight loss solutions. ReShape's exhibit opens at 9:25 AM ET on September 18. Mackie will cover topics including vitamin deficiencies post-surgery and nutritional guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

ReShape Lifesciences (NASDAQ: RSLS) announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021, at 2:05 p.m. ET. The presentation will be accessible via a webcast link provided in the announcement. An audio replay will be available for 90 days post-presentation. Management will also conduct one-on-one meetings during the summit. ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering FDA-approved products such as the Lap-Band® Program and innovative devices like the ReShape Vest™ System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
Rhea-AI Summary

ReShape Lifesciences (NASDAQ:RSLS) has appointed Al Diaz as Vice President of Operations and Research and Development. Mr. Diaz brings over 30 years of executive experience, previously serving as Executive VP at ClearFlow, Inc. His role will focus on enhancing manufacturing and R&D efforts post-merger with Obalon Therapeutics. Bart Bandy, CEO, expressed enthusiasm for Diaz’s addition to the team, emphasizing the importance of his leadership in driving profitability and expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
management
-
Rhea-AI Summary

ReShape Lifesciences (NASDAQ:RSLS) reported strong financial results for Q2 2021, achieving revenue of $3.5 million, up from $1.7 million in Q2 2020. The merger with Obalon Therapeutics enhances market positioning, while the launch of ReShape Marketplace TM expands its weight loss product ecosystem. The company raised $46 million in funding, eliminating debt and improving its balance sheet. Gross profit rose to $2.1 million from $0.8 million year-over-year. Total operating expenses increased to $5.9 million, with a reduced adjusted EBITDA loss of $1.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.38%
Tags
Rhea-AI Summary

ReShape Lifesciences Inc. (NASDAQ:RSLS) reported impressive preliminary results for Q2 2021, with revenues of $3.5 million, marking a 107% increase from $1.7 million in Q2 2020. The gross profit reached $2.1 million, reflecting a gross margin of 61%, up from 49% year-over-year. The company also completed a merger with Obalon Therapeutics, raised $46 million in funding, and transitioned manufacturing to a US-based firm. Cash and equivalents stood at $40.2 million as of June 30, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
-
Rhea-AI Summary

ReShape Lifesciences (NASDAQ:RSLS) announced CEO Bart Bandy's appearance on the Big Biz Show, highlighting the company's growth and product offerings.

Bandy expressed gratitude for the platform that showcases businesses on a growth trajectory. He emphasized recent milestones that position ReShape for continued success in the weight loss and metabolic health sector, reflecting the company's commitment to providing innovative health solutions.

The interview could be viewed on YouTube.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
-
Rhea-AI Summary

ReShape Lifesciences Inc. (NASDAQ:RSLS) will release its second quarter financial results on August 5, 2021, before markets open. CEO Bart Bandy expressed eagerness to share significant events and results during the announcement. A webinar will follow the release, providing insights into the financial performance and business updates. The company's portfolio includes the FDA-approved Lap-Band® Program, the investigational ReShape Vest™ System, and the reshape care™ virtual weight-management program. For more information, visit Investor Relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
conferences
Rhea-AI Summary

ReShape Lifesciences Inc. (NASDAQ:RSLS) has unveiled ReShape Marketplace™, an online platform providing a variety of wellness products supporting nutrition, exercise, sleep, and stress management. This initiative extends the company's existing reshape care™ telehealth service for weight loss. CEO Bart Bandy emphasizes the marketplace's role in aiding consumers on their health journeys. Products include portion control guides, weighted blankets, and more. This launch reinforces ReShape's commitment to becoming a leading source for comprehensive weight loss and wellness solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
none

FAQ

What is the current stock price of Reshape Lifesciences (RSLS)?

The current stock price of Reshape Lifesciences (RSLS) is $1.12 as of February 21, 2025.

What is the market cap of Reshape Lifesciences (RSLS)?

The market cap of Reshape Lifesciences (RSLS) is approximately 4.1M.

What is Reshape Lifesciences, Inc. focused on?

Reshape Lifesciences, Inc. is a medical device company focused on developing non-surgical weight loss devices for obese or overweight patients.

What are some of the products offered by Reshape Lifesciences?

Reshape Lifesciences offers a range of products including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation.

What is the goal of Reshape Lifesciences?

Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the demand for safe and effective options in the market.

How does Reshape Lifesciences contribute to the medical field?

Reshape Lifesciences contributes to the medical field by offering innovative and advanced technologies to treat obesity and metabolic diseases.
Reshape Lifesciences Inc.

Nasdaq:RSLS

RSLS Rankings

RSLS Stock Data

4.07M
666.88k
5.58%
1.83%
4.94%
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN CLEMENTE